Ziprasidone and psychosis in Parkinson disease [3]

Clinical Neuropharmacology

Volumn 28, Issue 5, 2005, Pages 254-

  Micheli, Federico ^a   Taubenslag, Nora ^a   Gatto, Emilia ^b   Scorticati, María Clara ^a  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^b Sanatorio Mitre   (Argentina)

Author keywords

Parkinson disease; Psychosis; Ziprasidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; QUETIAPINE; ZIPRASIDONE;

ADULT; AGED; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; HUMAN; LETTER; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS;

EID: 27644480037     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000185826.42443.ee     Document Type: Letter

References (1)

1. Gomez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol. 2005;28:111-114.